Dongcheng Biochem(SZ:002675) Zheng Quan Zhi Xing·2025-08-13 16:24Summary of Key Points Core Viewpoint The announcement from Yantai Dongcheng Pharmaceutical Group Co., Ltd. indicates that its controlling shareholder, Yantai Dongyi Biological Engineering Co., Ltd., has engaged in the pledge, extension, and release of part of its shares in the company. The overall risk associated with the share pledges is deemed manageable, with no current risk of forced liquidation. Group 1: Share Pledge Situation - The controlling shareholder Dongyi Biological has pledged 12,000,000 shares, accounting for 9.61% of its total holdings and 1.46% of the company's total shares [1]. - The purpose of the share pledge is for financing needs [1]. Group 2: Share Pledge Extension Situation - An additional 10,000,000 shares have been extended, representing 8.01% of the total shares pledged [2]. - The extension is also for financing purposes, with the new pledge period extending to 2026 [2]. Group 3: Share Release Situation - A total of 12,932,000 shares have been released from pledge, which is 10.35% of the total shares held by the controlling shareholder [2]. - The release of shares occurred on September 11, 2025 [2]. Group 4: Cumulative Pledged Shares - As of the announcement date, the cumulative pledged shares by Dongyi Biological and its concerted actions amount to 124,888,049 shares, which is 15.15% of the total shares held [2]. - The total number of pledged shares represents 30.46% of the total shares that are subject to restrictions [2]. Group 5: Risk Assessment - The financial condition of the controlling shareholder is reported to be good, with sufficient capacity to repay, indicating no current risk of forced liquidation or change in actual control [2].